Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.

Articles

HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

February 1st 2024

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Emerging Data for HER2 ADCs in Ovarian Cancer

January 25th 2024

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Landscape Surrounding HER2 ADCs in GI Cancers

January 25th 2024

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Targeting HER2 Alterations with ADCs in NSCLC

January 18th 2024

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Expert Insights on HER2-Directed ADCs in Breast Cancer

January 18th 2024

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors

January 11th 2024

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.

Exploring HER2 as a Pan Tumor Biomarker

January 11th 2024

Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

January 3rd 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

December 27th 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

December 27th 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC

December 20th 2023

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management

December 20th 2023

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

December 13th 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights

December 13th 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6th 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Navigating Uncommon Mutations in NSCLC Treatment Decisions

December 6th 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing

November 29th 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer

November 29th 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Advancement in NSCLC Precision Medicine: Biomarker Testing

November 17th 2023

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

October 31st 2023

Martin Dietrich, MD, PhD, presents key data from the phase 3 MARIPOSA-2 study, which investigated amivantamab plus chemotherapy, with or without lazertinib, versus chemotherapy in patients with EGFR-mutated advanced NSCLC who experienced disease progression on osimertinib.